May 11, 2020 / 03:30PM GMT
Operator
Ladies and gentlemen, welcome to the AB Science web conference. I would like now to hand over to Alain Moussy and Jean-Pierre Kinet. Gentlemen, please go ahead.
Alain Moussy - AB Science S.A. - Co-Founder, Chairman, President, CEO & Scientific Director
Good evening, and good afternoon for the ones in the United States. Thank you to join us for our web conference, where we're going to discuss this new clinical study, evaluating masitinib combination with isoquercetin in COVID-19. The presentation is going to be structured in 3 parts. With me Jean-Pierre Kinet, who is the Co-President of the Scientific Committee of AB Science, will describe the rationale, the scientific rationale behind this trial, and the combination of masitinib and isoquercetin in COVID-19. And then I will describe the 2 remaining parts of the presentation, the differentiating positioning of masitinib and the design of the study. And after this presentation, there should be less than 30 minutes, we'll open it for your questions as usual. So the call should be less than 1 hour.
So
AB Science SA to Discuss Masitinib and Isoquercetin in COVID-19 - Conference Call Transcript
Feb 12, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers